New York, Feb 20, 2026, 08:49 EST — Premarket
- HLF slips 0.6% premarket, following that 18.3% surge in the previous session.
- Herbalife is projecting sales growth of 1% to 6% for 2026, with adjusted EBITDA expected to come in between $670 million and $710 million.
- Cristiano Ronaldo put $7.5 million into Pro2col Software, picking up a 10% ownership stake.
Herbalife Ltd (NYSE: HLF) pulled back 0.6% to $19.46 ahead of Friday’s open, cooling off after an 18.3% surge the previous session. The stock hit $20.34 — setting its 52-week high. Over the past year, shares have ranged from $6.20 up to that mark. (Investing)
Herbalife’s business—weight loss and supplements, all distributed via independent sellers—has a reputation for volatility, especially when moods shift. Shares surged after earnings, but now, investors are sizing up whether the company’s guidance boost and a fresh tech initiative, this time with celebrity backing, are enough to hold that momentum once trading starts. (Reuters)
Herbalife reported a 6.3% bump in fourth-quarter net sales on Feb. 18, bringing the figure to $1.28 billion. Adjusted EBITDA landed at $156.1 million. For 2026, the company is aiming for reported net sales growth in the 1%–6% range and sees adjusted EBITDA between $670 million and $710 million. Elsewhere, soccer icon Cristiano Ronaldo has put $7.5 million into Pro2col Software, picking up a 10% stake. (Herbalife Ltd.)
Ronaldo described the investment as “felt like a natural evolution,” according to TipRanks, building on what started out as a paid endorsement deal. Mizuho Securities’ John Baumgartner weighed in, labeling the partnership with Ronaldo “a nice add” for Herbalife. (TipRanks)
Citi bumped its price target on Herbalife up to $21 from $17, sticking with a Buy rating. The firm, in a note cited by TheFly on TipRanks, called the latest quarter strong and highlighted “momentum entering 2026.” (TipRanks)
Herbalife’s 8-K, including its earnings release, landed in an SEC filing on Feb. 18. That same day, the investor-relations site posted a Form 10-K annual report and insider ownership documents. (SEC)
During the earnings call, executives said the Pro2col system will launch commercially in the U.S. in July, with small bolt-on deals also on the radar. “We are interested … in companies that are relatively small,” CFO John DeSimone told listeners. (The Motley Fool)
The upside isn’t straightforward here. Herbalife noted its guidance already factors in early estimates tied to the latest round of tariffs starting Feb. 17, plus the old standbys—currency volatility, regulatory uncertainty, and distributor network health. China net sales dropped 4.4% in the fourth quarter, North America edged down 0.8%. Investors can’t seem to let those two pressure points go. (Nasdaq)
The rally’s driven the stock near its yearly highs again, narrowing the cushion for any misstep on margins or distributor moves. Should costs cut deeper than planned or the Pro2col rollout falter, that 2026 forecast might suddenly seem a stretch.
All eyes shift to the next test: will the stock keep its gains when the bell rings at 9:30 a.m. ET? Investors are tracking follow-through volume after that earnings-fueled jump.
